Apollo Life Sciences: Diabetes Advisor Board


Professor Paul Zimmet AO Head of International Diabetes Institute, Melbourne
"The data that I have seen so far makes this one of the most forward looking and best prospects of an oral insulin"
Click here to see Paul Zimmet's view on Apollo's oral insulin


Bill Moss AM Non-Executive Director and Investor
"Apollo has a number of opportunities to grow into the future. Opportunities perhaps that are much greater than many other companies many times their size"
Click here to hear Bill Moss's view on investing in Apollo